HomeREGULATORY
REGULATORY

CSIMC Recommends NHI Price Listing for 15 APIs/20 Products
(Sep.7.2011)

At a general meeting on September 7, the Central Social Insurance Medical Council (CSIMC; Chuikyo) recommended NHI price listing for 15 APIs (active pharmaceutical ingredients)/20 products, including AstraZeneca’s proton pump inhibitor (PPI) Nexium capsule 10 mg and 20 mg (esomeprazole magnesium) and Astellas Pharma’s treatment for overactive bladder Betanis Tablet 25 mg and 50 mg (mirabegron). The adrenal hormone preparation EpiPen Injection 0.15 mg and 0.3 mg (adrenaline) will be added to the NHI price list on September 22. Other products will be included in the NHI price list on September 12.
> Read full story

Commentary

Ex-Health Minister Tamura’s Clout Likely to Grow in Nagatacho

Lexicon

PMDA-WEST:
医薬品医療機器総合機構関西支部

The Column

3 Reasons Why KOL Management Is No Longer Enough

Archives

Takeda Gains Worldwide Exclusive Rights for Amitiza Excluding Japan and China from Sucampo(Oct.24)
Toray Licenses Hemodialysis Pruritus Treatment to Orient EuroPharma in Taiwan(Oct.24)
Health Ministry Panel Agrees to Regulate Clinical Research by Law(Oct.24)
MHLW Orders Revision of Package Insert for Xtandi(Oct.24)
MHLW Orders Revision of Package Inserts for Acetaminophen(Oct.24)

Most Read

1.
MHLW to Report ...
2.
Takeda Tops Phy...
3.
Pfizer Japan Vo...
4.
JMA Pres. Frets...
5.
Bayer AG Aims t...

News Calendar